Cell counts as a function of NSAID administration.

(A) Effects of E, etodolac, 300 mg twice a day for 3 to 6 days, compared with 9 other NSAIDs: N, naproxen, 250 mg twice a day for 4 days; D, diclofenac, 50 mg 3 times a day for 4 days; S, sulindac, 200 mg twice a day for 4 days; R, nabumetone 500 mg twice a day for 6 days; O, oxaprozin, 600 mg twice a day for 4 days; P, piroxicam, 20 mg every day for 3 days; I, indomethacin, 25 mg 3 times a day for 3 days; T, tolmetin, 400 mg twice a day for 3 days; and M, ibuprofen, 400 mg 3 times a day for 3 days. (B) Effects of C, celecoxib, 100 mg twice a day for 4 days; V, rofecoxib, 25 mg every day for 4 days; F, flurbiprofen, 100 mg 3 times a day for 3 days; and X, meloxicam, 7.5 mg every day for 3 days. (C) Effect of a 4-month course of etodolac. A 400 mg sustained release preparation was administered twice a day from July 20, 1998 until July 28, 1998, followed by 300 mg twice a day of the standard release preparation until September 8, 1998, followed by reinstitution of the 400 mg sustained release preparation twice a day. There was a rapid decline in the lymphocyte count in the first several days to a nadir of 12 510 followed by rebound and gradual increase to 33 968 on November 23, 1998, the last day of etodolac administration. After discontinuation of etodolac, there was a rapid rise of the lymphocyte count to 43 132 on November 30, 1998, and to 50 199 on December 16, 1998. To determine if a full response to etodolac was still possible after a prolonged course, etodolac was administered at 400 mg sustained release twice per day for 2 days from December 19, 1998, to December 21, 1998. The lymphocyte count on December 21, 1998, dropped to 24 548 with a rapid return to 59 148 by December 28, 1998.